For savvy investors looking for long-term businesses that not only dominate their industries today but also have the ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

(RTTNews) - Eli Lilly and Co. (LLY) announced Friday the successful completion of its acquisition of Verve Therapeutics, Inc. (VERV). Verve is a Boston-based clinical-stage company developing ...

Europe's CHMP has issued positive opinions on Eli Lilly's Alzheimer's treatment Kisunla and Gilead's breakthrough PrEP drug Yeytuo.